Fujioka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fujioka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Mika Takahashi
Department of Dermatology Hirosaki University Graduate School of Medicine Hirosaki Japan
1 shared publication - Naoko Kamano
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
1 shared publication Naomasa Kakiya
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
1 shared publication- Naoto Watamura
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science
1 shared publication - Nobuhisa Iwata
Department of Genome-based Drug Discovery, Graduate School of Biomedical Sciences, Nagasaki University
1 shared publication - Per Nilsson
Department of Neurobiology Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
1 shared publication
Latest Publications
- 6 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (848) , eadk1822
The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain
Deposition of amyloid-β (Aβ) in the brain can impair neuronal function and contribute to cognitive decline in Alzheimer’s disease (AD). Here, we found that dopamine and the dopamine precursor levodopa (also called l -DOPA) induced Aβ degradation in the brain. Chemogenetic approaches in mice revealed that the activation of dopamine release from ventral tegmental area (VTA) neurons increased the abundance and activity of the Aβ-degrading enzyme neprilysin and reduced the amount of Aβ deposits in the prefrontal cortex in a neprilysin-dependent manner. Aged mice had less dopamine and neprilysin in the anterior cortex, a decrease that was accentuated in AD model mice. Treating AD model mice with levodopa reduced Aβ deposition and improved cognitive function. These observations demonstrate that dopamine promotes brain region–specific, neprilysin-dependent degradation of Aβ, suggesting that dopamine-associated strategies have the potential to treat this aspect of AD pathology.
- 6 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (848) , eadk1822
The dopaminergic system promotes neprilysin-mediated degradation of amyloid-β in the brain
Deposition of amyloid-β (Aβ) in the brain can impair neuronal function and contribute to cognitive decline in Alzheimer’s disease (AD). Here, we found that dopamine and the dopamine precursor levodopa (also called l -DOPA) induced Aβ degradation in the brain. Chemogenetic approaches in mice revealed that the activation of dopamine release from ventral tegmental area (VTA) neurons increased the abundance and activity of the Aβ-degrading enzyme neprilysin and reduced the amount of Aβ deposits in the prefrontal cortex in a neprilysin-dependent manner. Aged mice had less dopamine and neprilysin in the anterior cortex, a decrease that was accentuated in AD model mice. Treating AD model mice with levodopa reduced Aβ deposition and improved cognitive function. These observations demonstrate that dopamine promotes brain region–specific, neprilysin-dependent degradation of Aβ, suggesting that dopamine-associated strategies have the potential to treat this aspect of AD pathology.